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Alanine aminotransferase (ALT) catalyses a transamination reaction that links 
carbohydrate and amino acid metabolism. In this study, we examined the effect of silencing 
cytosolic ALT (cALT) expression on the hepatic metabolism in Sparus aurata. A number of 
siRNA and shRNA designed to down-regulate cALT expression were validated in HEK-293 
cells transfected with plasmids expressing S. aurata cALT or mitochondrial ALT (mALT) 
isoforms: ALT silencing significantly decreased the expression levels of S. aurata mRNA 
cALT1 to 62 % (siRNA) and 48 % (shRNA) of the values observed in control cells. The 
effect of cALT silencing was analysed in the liver of S. aurata 72 h after intraperitoneal 
injection of chitosan-tripolyphosphate (TPP) nanoparticles complexed with a plasmid 
encoding a shRNA to down-regulate cALT expression (pCpG-si1sh1). In fish fed diets with 
different ratio of protein to carbohydrate and treated with chitosan-TPP-pCpG-si1sh1, cALT1 
and cALT2 mRNA levels significantly decreased irrespective of the diet. Consistently, ALT 
activity decreased in liver of treated animals. In the liver of S. aurata treated with chitosan-
TPP-pCpG-si1sh1 nanoparticles, down-regulation of cALT expression increased the activity 
of key enzymes in glycolysis (6-phosphofructo-1-kinase and pyruvate kinase) and protein 
metabolism (glutamate dehydrogenase). Besides showing for the first time that administration 
of chitosan-TPP-pCpG-si1sh1 nanoparticles silences hepatic cALT expression in vivo, our 
data support that down-regulation of cALT could improve the use of dietary carbohydrates to 
obtain energy and spare protein catabolism. 
 





Alanine aminotransferase (ALT; EC 2.6.1.2) links amino acid and carbohydrate metabolism 
through catalysing the reversible transamination reaction between L-alanine and 2-
oxoglutarate to form pyruvate and L-glutamate. Two ALT isoforms, ALT1 and ALT2, each 
encoded by a different gene, have been isolated in mammals (Sohocki et al. 1997; Yang et al. 
2002; Jadhao et al. 2004). In teleost fish, the hepatic levels of ALT activity were referred as a 
good indicator of protein utilisation (Fynn-Aikins et al. 1995; Sanchez-Muros et al. 1998; 
Metón et al. 1999; Fernández et al. 2007). We previously reported the presence of three ALT 
isoforms in gilthead sea bream (Sparus aurata): two cytosolic isoforms resulting from 
alternative splicing of cALT gene (cALT1 and cALT2) and a mitochondrial enzyme (mALT) 
(Metón et al. 2004; Anemaet et al. 2008). cALT1 is expressed mainly in liver, brain, skeletal 
muscle, intestine and kidney of S. aurata. Higher cALT2 mRNA levels are found in heart, 
gill or spleen. Moderate expression levels of cALT2 are also observed in intestine, kidney 
and liver. The hepatic expression of cALT2 increases under gluconeogenic conditions such as 
starvation, while cALT1 is predominant in postprandial periods for utilisation of dietary 
nutrients. Thus, cALT1 is the most contributing cytosolic isoform to ALT activity in liver of 
fed fish (Anemaet et al. 2010). 
RNA interference (iRNA) confers an effective mechanism for specific silencing of 
target mRNAs (Fire et al. 1998; Elbashir et al. 2001; Sifuentes-Romero et al. 2011). Plasmids 
or viral vectors can express small interfering RNAs (siRNAs) as short hairpin RNAs 
(shRNAs) to induce specific iRNA silencing effects. For the development of iRNA-based 
therapies and to unravel the molecular knowledge of enzymatic pathways and functional 
genomic studies, the delivery methods of iRNA-mediating agents is one of the major 
obstacles. Although viral vectors seem to be highly efficient nucleic acid carriers, safety 
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concerns such as cytotoxicity, oncogenicity, and immunogenicity limit their potential use. 
Non-viral vectors such as shRNA expression plasmids have the advantages of no integration 
into the host chromosome, low cost and high efficiency for gene silencing in fish cell lines 
and tissues (Su et al. 2008; Zenke and Kim 2008; Terova et al. 2013). 
The high positive charge of chitosan allows interaction with negatively charged nucleic 
acids to form based systems for delivery of plasmid DNA and siRNAs into cells (Roy et al. 
1999; Mao et al. 2001; Mansouri et al. 2004; Ramos et al. 2005; Mao et al. 2010; Guo et al. 
2010; Ragelle et al. 2013; Ragelle et al. 2014). For aquaculture purposes, chitosan has been 
used for encapsulation of vaccines. However, the use of shRNA-chitosan particles to perform 
functional genomic studies in fish is relatively unexplored (Zenke and Kim 2008; Sifuentes-
Romero et al. 2011; Borgogna et al. 2011). To our knowledge, no studies have addressed 
knockdown of ALT gene expression and the effect of ALT silencing on the intermediary 
metabolism.  
In carnivorous fish, dietary amino acids are used not only as building blocks for protein 
synthesis, but also as important substrates for energy production and gluconeogenesis. 
Instead, these animals have a limited capacity for dietary carbohydrate utilisation. This 
metabolic profile mimics non-insulin-dependent diabetes mellitus in mammals after a glucose 
load and led to consider carnivorous fish as glucose intolerant (Cowey and Walton 1989; 
Moon 2001; Hemre et al. 2002). We previously reported that amino-oxyacetate (AOA)-
mediated inhibition of cALT activity could favour the use of dietary carbohydrates in liver of 
S. aurata (González et al. 2012). In the present study, we hypothesised that administration of 
chitosan nanoparticles complexed with a plasmid expressing a shRNA to knockdown cALT 
expression in liver could improve carbohydrate utilisation for energy demands in S. aurata, 





Material and Methods 
 
Experimental design and procedures 
 
Gilthead seabream (Sparus aurata) juveniles (5 g) were obtained from Piscimar (Andromeda 
Group, Burriana, Castellón, Spain) and maintained in our facilities distributed in aquaria of 
260 L at a temperature of 21 °C. Facilities and maintenance procedures were previously 
described (Fernández et al. 2007). To validate chitosan-TPP nanoparticles as a vehicle to 
deliver the expression plasmids pCpG-siRNA (long lasting expression plasmid of siRNAs; 
InvivoGen, San Diego, CA, USA), pCpG-siRNA-Scramble (control plasmid that expresses a 
scramble sequence with no homology with known sequences; InvivoGen, San Diego, CA, 
USA), and pCpG-si1sh1 (expression plasmid encoding a shRNA to down-regulate cALT 
expression) to S. aurata liver, fish were fed a commercial diet (Microbaq, from Dibaq 
Diproteg, S.A., Segovia, Spain) for 30 days at 2 % body weight (BW). Thereafter, fish were 
intraperitoneally injected with chitosan-tripolyphosphate (TPP) nanoparticles complexed with 
pCpG-siRNA (10 µg of plasmid per gram of BW). In a second experiment, to determine the 
metabolic effect of pCpG-si1sh1, fish were fed for 30 days with two diets differing in the 
protein to carbohydrate ratio, P60 and P45 (Table 1) before treatment. For both experiments 
and to obtain tissue samples, animals were anesthetised with MS-222 (1:12,500) before 
handling to prevent stress (9:30 a.m.) and killed by cervical section. Blood was collected, and 
liver samples were immediately frozen in liquid N2 and kept at -80 °C until use. The 
experimental procedures complied with the guidelines of the Animal Use Committee of the 





Construction of the expression plasmids 
 
The coding sequence of cALT1 was obtained by PCR using oligonucleotides JDAL16 and 
IMAL20 (Table 2) and the previously described pcALT-GFP as template [9]. To amplify the 
coding domain sequence of mALT, a PCR using primer pair JDAL26/IMAL24 (Table 2) and 
the previously described pmALT-GFP as template was carried out [9]. The coding sequence 
of cALT2 was obtained by RT-PCR using total RNA isolated from S. aurata liver and 
oligonucleotides JDAL36 and IMAL20 (Table 2), designed from the previously isolated 
cALT2 messenger (Anemaet et al. 2008). For the three constructs, PCR products were ligated 
into pcDNA3 (Life Technologies, Carlsbad, CA, USA) previously digested with HindIII and 
BamHI, to generate pcDNA3-cALT1, pcDNA3-mALT and pcDNA3-cALT2, respectively. 
To obtain pCpG-si1sh1, primers JDsi1sh1s and JDsi1sh1as (Table 2) were mixed at a 
final concentration of 25 µM each, heated at 90 ºC for 1 min and then cooled down at room 
temperature. One hundred ng of the double-stranded product were ligated into pCpG-siRNA  
previously digested with HindIII and Acc65I.  
 
 
Cell culture and transfection 
 
The human embryonic kidney derived cell line HEK-293 (ATCC CRL-1573) was cultured in 
modified Essential medium (MEM), supplemented with 10% foetal bovine serum, 90 IU/l 
penicillin, 90 µg/ml streptomycin and 2 mM glutamine. The cells were grown at 37 ºC in 5 % 
CO2. One day before transfection, 5 x 105 cells were seeded per well in six-well plates. For 
gene knockdown experiments using siRNAs, transfections were performed using 3 to 300 ng 
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cALT1, cALT2 or mALT expression vectors, 20 to 100 nM siRNA and 4 µl of lipofectamine 
2000 (Life Technologies, Carlsbad, CA, USA) following manufacturer instructions. For gene 
silencing assays with shRNA expression vectors, the calcium phosphate co-precipitation 
method was used to transiently transfect the cells with 30 ng pcDNA3-cALT1 and 30 to 600 
ng pCpG-si1sh1 or pCpG-siRNA-Scramble. To correct for variations in transfection 
efficiency, 300 ng of CMV-b plasmid (lacZ) was included in each transfection. To ensure 
equal DNA amounts, empty plasmids were added in each transfection. The cells were 
harvested 24 to 72 h later washed in PBS, lysed and used to isolate total RNA. β-
Galactosidase activity in the clear lysate was determined as described elsewhere (Metón et al. 
2006). siRNA1 targeting cALT1 (Table 2) was custom designed and synthesised by Bionova 
Cientifica, S.L. (Madrid, Spain). 
 
 
Semi-quantitative RT-PCR  
 
Total RNA was isolated from S. aurata liver by the Total Quick RNA Cells & Tissues kit 
(Talent, Trieste, Italy). Three µg of total RNA was reverse-transcribed to cDNA by 
incubation with 5x First Strand Buffer (Life Technologies, Carlsbad, CA, USA), 10 mM 
dithiothreitol, 0.5 mM dNTPs, 6.25 ng/µl random hexamers, 1 U/µl RNasin (Promega, 
Southampton, UK) and 10 U/µl Moloney murine leukemia virus RT (Life Technologies, 
Carlsbad, CA, USA) for 1 h at 37 ºC. The cDNA product and specific oligonucleotides to 
amplify alpha peptide of Escherichia coli b-galactosidase (JDpepalphaS and JDpepalphaAS; 
Table 2) and S. aurata β-actin (BA0199 and BA0299; Table 2) were used subsequently for 
PCR. After initial denaturation at 95 ºC for 3 min, a number of cycles between 20 and 35 at 
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95º for 30 sec, 68 ºC for 30 sec, and 72 ºC for 1 min, with a final extension step at 72 ºC for 7 
min, were performed to verify that the PCR products amplify linearly and to determine the 
optimal number of cycles allowing detection without saturation of the signal. The PCR 





Five micrograms of total RNA isolated from HEK-293 cells or S. aurata liver were reverse-
transcribed to cDNA using Moloney murine leukemia virus RT (Life Technologies, Carlsbad, 
CA, USA) for 1 h at 37 ºC in the presence of random hexamer primers. The cDNA product 
was used for subsequent quantitative real time PCR (qRT-PCR). The mRNA levels of S. 
aurata cALT1, cALT2 and mALT were determined in an ABI Prism 7000 Sequence 
Detection System (Applied Biosystems) using 0.4 µM of each primer, 10 µl of SYBR Green 
(Applied Biosystems), and 1.6 µl of the diluted cDNA product in a final volume of 20 µl. 
Primer pairs used were JDc1s/JDc1as, JDc2s/JDc2as and JDm1s/JDm1as for S. aurata 
cALT1, cALT2 and mALT, respectively (Table 2). The amount of mRNA for the genes of 
interest in transiently transfected HEK-293 cells was normalised with human hypoxanthine-
guanine phosphoribosyltransferase (HPRT) using primer pair JDRTPHPRTs/JDRTPHPRTas 
(Table 2). For in vivo experiments, normalisation of mRNA levels was carried out assessing 
S. aurata b-actin expression with primer pair JDBAs/JDBAas (Table 2). To correct for 
variations in transfection efficiency in the experiments performed on HEK-293 cells, mRNA 
were normalised with β-galactosidase expression using oligonucleotides JDpcmv1s and 






Western blot analysis 
 
Forty micrograms of hepatic protein extract was loaded per lane in a 10% PAGE-SDS gel. 
After electrophoresis the gel was equilibrated in transfer buffer (25 mM Tris-HCl, 192 mM 
glycine, 20% methanol, pH 8.3) and electroeluted onto NytranN nylon membranes 
(Whatman, Kent, UK) for 3 h at 60 V at 4 °C. A rabbit polyclonal antibody raised against S. 
aurata ALT was used as primary antibody (1:1000). Immunodetection of ALT protein was 
performed with the Immun-Star™ Substrate Kit (Bio-Rad, Hercules, CA, USA). 
 
 
Enzyme activity assays 
 
Enzyme activities were assayed in crude extracts obtained from powdered frozen liver (1:5, 
w/v) homogenised in buffer H (50 mM Tris-HCl pH 7.5, 4 mM EDTA, 50 mM NaF, 0.5 mM 
PMSF, 1 mM DTT and 250 mM sucrose) with a PTA-7 Polytron (Kinematica GmbH, Littau-
Luzern, Switzerland) (position 3, 30 s). After centrifugation at 20,000 g for 30 min at 4 ºC, 
the supernatant was collected and used to determine enzyme activities. ALT and aspartate 
aminotransferase (AST; EC 2.6.1.1) were assayed using commercial kits (Linear Chemicals, 
Montgat, Barcelona, Spain). Assays for 6-phosphofructo-1-kinase (PFK-1; EC 2.7.1.11), 
pyruvate kinase (PK; EC 2.7.1.40), fructose-1,6-bisphosphatase (FBPase-1; EC 3.1.3.11), 
glucose-6-phosphate dehydrogenase (G6P-DH; EC 1.1.1.49) and 6-phosphogluconate 
dehydrogenase (6PG-DH; EC 1.1.1.44) and glutamate dehydrogenase (GDH; EC 1.4.1.2) 
were previously described (Metón et al. 1999; Bibiano Melo et al. 2006). Protein content in 
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extracts was determined by the Bradford method at 30 °C using bovine serum albumin as a 
standard (Bradford 1976). Spectrophotometric determinations were performed at 30 °C in a 
Cobas Mira S analyser (Hoffman-La Roche, Basel, Switzerland).  
 
 
Preparation of chitosan-TPP-plasmid nanoparticles 
 
Chitosan-TPP-plasmid nanoparticles were prepared using the modified version of the ionic 
gelation method (Calvo et al. 1997). Briefly, low molecular weight chitosan (Sigma-Aldrich, 
MA, USA) was added to acetate buffer solution at pH 5.0 to reach a final concentration of 2 
mg/ml. The mixture was shaken for 3 hours under vigorous magnetic stirring in order to get 
chitosan dissolved in acetate buffer. Then it was filtered to remove any traces of undissolved 
chitosan. Three-hundred µg of plasmid DNA (pCpG-siRNA, pCpG-siRNA-Scramble or 
pCpG-si1sh1), previously linearised by restriction with SacI (Fermentas, Madrid, Spain), 
were added to 1.2 ml of a 0.84 mg/ml TPP (Panreac, Castellar del Vallès, Barcelona, Spain) 
solution, and then the TPP-plasmid solution was added dropwise to 3 ml of the previously 
prepared chitosan solution (1:0.4 chitosan:TPP ratio) under magnetic stirring at 800 rpm 
(Fàbregas et al. 2013). Nanoparticles were recovered by centrifugation (12000 rpm at 15 ºC 
for 10 min). The chitosan-TPP-plasmid complexes were gently rinsed twice with ultrapure 
water and resuspended through vortex shaking with a 2 ml mannitol solution at 2% w/v, 
which acted as a cryoprotectant during lyophilisation. Nanoparticles were subjected to a 
freeze-drying process at -47 ºC. In order to remove internal residual water molecules that 
may not be frozen, a secondary drying was held at 25 ºC. Two hours before administration to 





Characterisation of the nanoparticles 
 
Morphological characterisation of the nanoparticles was performed by atomic force 
microscopy using peak force tapping mode (Multimode 8 AFM attached to a Nanoscope III 
Electronics, Bruker, USA). The Z potential values, as a measure of surface charge, were 
determined by means of laser Doppler microelectrophoresis using a Zetasizer NanoZ 






Data were analysed by one-way and two-way ANOVA using a computer program (IBM 
SPSS Statistics, Armonk, NY, USA). One-way statistical analysis with two levels was 
determined using Student’s t-test. One-way ANOVA statistical differences among three or 





siRNA-mediated knockdown of S. aurata cALT isoforms in HEK-293 cells  
 
HEK-293 cells were used to validate candidate siRNA sequences to knockdown S. aurata 
cALT expression in vitro. After transfection of HEK-293 cells with constructs expressing S. 
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aurata cALT1 (pcDNA3-cALT1), cALT2 (pcDNA3-cALT2) or mALT (pcDNA3-mALT), 
the expression level of ALT isoforms was assessed by measuring ALT activity in cytosolic 
and mitochondrial cellular fractions. Thereafter, four different siRNAs designed to silence S. 
aurata cALT isoforms were assayed to select the siRNA responsible for the highest 
knockdown effect on S. aurata cALT1 expression. Twenty-four h after transfection with 20 
nM of each siRNA, 30 ng of pcDNA3-cALT1 and 300 ng of pCMV-β as an internal control 
for transfection efficiency, the cells were lysed and RNA isolated to perform a qRT-PCR 
assay to determine cALT1 expression levels. The highest ALT gene silencing effect was 
observed using the siRNA herein named siRNA1. Two siRNAs (siRNA2 and siRNA4) did 
not show any effect on cALT1 mRNA levels (data not shown). Therefore, siRNA1 was 
selected to perform subsequent functional genomic studies. Optimal concentration of the S. 
aurata cALT1 plasmid and time post-transfection (24 to 72 h) to improve an ALT 
knockdown effect in HEK-293 cells co-transfected with 20 nM siRNA1 was assayed through 
analysis of cALT1 expression by qRT-PCR. To this end, cALT1 silencing efficiency of 
siRNA1 was firstly analysed 24 h post-transfection in HEK-293 cells co-transfected with 
different amounts of the S. aurata cALT1 expression plasmid (pcDNA3-cALT1, ranging 
from 3 ng to 300 ng). As shown in Fig. 1a, a significant cALT1 silencing effect trigger by 
siRNA1 was observed when cells were transfected with at least 30 ng of pcDNA3-cALT1, 
which reduced S. aurata cALT1 mRNA levels to about 62 % of the values observed in cells 
not treated with siRNA. The decreased cALT1 expression observed using 30 ng of pcDNA3-
cALT1 was even higher, although not significantly different, than using 300 ng of pcDNA3-
cALT1.  
In HEK-293 cells transfected with 20 ng of siRNA1, 30 ng de pcDNA3-cALT1 and 
300 ng of pCMV-β, qRT-PCR assays were performed to determine cALT1 expression from 
data obtained after 24 h, 48 h and 72 h post-transfection. The highest decrease in cALT1 
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mRNA levels (to 66 % of the values in non-treated cells) was observed 24 h after cell 
transfection. Extended post-transfection times did not allow a greater knockdown effect on 
cALT1 expression (Fig. 1b). 
In addition, we also studied the effect of siRNA1 on the expression of other S. aurata 
ALT isoforms (cALT2 and mALT) expressed in HEK-293 cells. To this end, HEK-293 cells 
were transfected in the presence or absence of 50 nM siRNA1, 300 ng of pCMV-β and 30 ng 
of either pcDNA3-cALT2 or pcDNA3-mALT. As expected, transfection with siRNA1 
caused a significant knockdown effect in cALT2 mRNA levels to 79 % of the values found in 
the cells not treated with siRNA (Fig. 1c). However, siRNA1 did not affect mALT expression 
in transfected cells. 
 
 
shRNA-mediated knockdown of S. aurata cALT1 in HEK-293 cells 
 
Since siRNA1 was able to knockdown the expression of S. aurata cALT isoforms at mRNA 
level in HEK-293 cells, and considering that siRNAs have a short half-life inside the cells, 
we designed a shRNA based on the siRNA1 sequence and cloned it into pCpG-siRNA, a 
plasmid designed for long lasting expression of siRNAs in vivo as the plasmid does not 
induce inflammatory responses and gene silencing by methylation in vertebrate hosts. The 
cALT1 silencing efficiency in vitro of the resulting plasmid (pCpG-si1sh1) was assayed by 
transfection of HEK-293 cells with 30 ng of pcDNA3-cALT1, 300 ng of pCMV-β and 
different amounts of pCpG-si1sh1. Forty-eight h following transfection, the cells were lysed 
and total RNA isolated to determine cALT1 mRNA levels by qRT-PCR. Transfection with 
300 ng and 600 ng pCpG-si1sh1 caused a significant decrease in cALT1 mRNA levels to 





Administration of chitosan-TPP-pCpG-siRNA allows expression of E. coli b-galactosidase 
alpha peptide in the liver of S. aurata 
 
To study the effect of cALT silencing on intermediary metabolism in vivo, we focused first 
on finding an appropriate method to deliver pCpG-si1sh1 into S. aurata liver cells. To assess 
the use of chitosan-TPP as a vehicle to deliver recombinant DNA to S. aurata, chitosan-TPP 
nanoparticles were complexed with the plasmid pCpG-siRNA, which encompasses an EM7-
LacZ alpha peptide cassette that allows expression of amino acids 10-85 of E. coli b-
galactosidase. Atomic force microscopy of chitosan-TPP nanoparticles showed a rounded 
morphology with mean diameter size of 193.3 ± 52.8 nm (n=3). The mean Z potential of 
chitosan-TPP samples was 32,0 ± 1,0 mV (n=3). Similarly as for chitosan-TPP, images of 
chitosan-TPP particles complexed with plasmid DNA (pCpG-siRNA) obtained with atomic 
force microscopy indicated a mean size of 246.0 ± 73.7 nm (n=3). The mean Z potential of 
chitosan-TPP-plasmid DNA particles was 14.4 ± 1.3 mV (n=3) (Fig. 3a). Two groups of fish 
received an intraperitoneal injection of either chitosan-TPP-pCpG-siRNA (10 µg of plasmid 
per gram BW) or chitosan-TPP nanoparticles (control fish). Twenty-four h after injection, the 
liver was excised and total RNA was isolated. Expression of bacterial b-galactosidase alpha 
peptide and S. aurata β-actin (endogenous constitutive expression gene) was analysed by 
semi-quantitative RT-PCR in the liver of fish administered with chitosan-TPP-pCpG-siRNA 
and control animals. Since the bacterial b-galactosidase alpha peptide is not present in 
vertebrate tissues, as expected the mRNA levels of this gene were not detected in control 
animals. However, bacterial b-galactosidase alpha peptide expression was observed in the 
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liver of all individuals administered with the chitosan-TPP-pCpG-siRNA complex (Fig. 3b). 
Although b-galactosidase alpha peptide mRNA was detected in the liver of all treated fish, 
the expression levels differed depending on the individual. This may be due to variations in 
the quantity of nanoparticles reaching the liver or in the number of transfected hepatic cells. 
To exclude whether administration of chitosan-TPP and chitosan-TPP complexed with 
pCpG-siRNA nanoparticles might affect blood glucose levels and the hepatic ALT activity, 
these parameters were analysed in S. aurata intraperitoneally injected with saline, chitosan-
TPP or chitosan-TPP-pCpG-siRNA. No differences in glycemia levels and ALT activity were 
found among the three groups of fish 72 h after treatment (data not shown). 
 
 
Effect of cALT silencing on liver intermediary metabolism 
 
The fact that administration of chitosan-TPP-pCpG-siRNA nanoparticles allowed 
expression of bacterial alpha peptide in the liver, prompted us to prepare chitosan-TPP 
complexed with pCpG-si1sh1 and analyse metabolic effects due to cALT silencing in S. 
aurata. To this end, chitosan-TPP, chitosan-TPP-pCpG-siRNA-Scramble (10 µg of plasmid 
per gram BW) or chitosan-TPP-pCpG-si1sh1 (10 µg of plasmid per gram BW) were 
intraperitoneally injected to three groups of S. aurata fed on Microbaq diet. Seventy-two h 
following treatment, cALT1 and cALT2 mRNA levels, immunodetectable ALT protein and 
enzyme activity corresponding to ALT and AST were determined in liver samples. As shown 
in Figs. 4a and 4b, cALT1 mRNA levels and ALT enzyme activity in S. aurata administered 
with chitosan-TPP-pCpG-si1sh1 significantly decreased to a 63 % and 70 %, respectively, of 
the values found in the group of animals treated with chitosan-TPP. Although not significant, 
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a similar tendency to decrease cALT2 expression was also observed in pCpG-si1sh1-treated 
fish (88 % of the values in controls). Consistently, administration of pCpG-si1sh1 caused a 
significant reduction of immunodetectable ALT protein levels in liver crude extracts 
compared to the values obtained in controls (fish intraperitoneally injected with chitosan-TPP 
or chitosan-TPP-pCpG-siRNA-Scramble). No significant differences were found in AST 
activity values among the three groups of animals. 
To determine whether knockdown of cALT expression mediated by pCpG-si1sh1 
depends on the nutrient composition of the diet, we intraperitoneally injected chitosan-TPP, 
chitosan-TPP-pCpG-siRNA-Scramble or chitosan-TPP-pCpG-si1sh1 to two groups of S. 
aurata fed 25 days on diets differing in the protein/carbohydrate ratio, diet P60 (high protein 
and low carbohydrate content) and P45 (low protein and high carbohydrate content). ALT 
activity and mRNA levels of cALT1, cALT2 and mALT isoforms were analysed in liver 
samples of S. aurata 72 h after treatment (Fig. 5). Consistent with previous results, the 
highest ALT activity was found in the animals fed the high protein/low carbohydrate diet 
(P60) (Metón et al. 1999; Fernández et al. 2007; González et al. 2012). Correspondingly, 
increased cALT1 and cALT2 mRNA levels were observed in the animals fed diet P60. 
However, mALT expression remained unaffected by diet composition. Administration of 
chitosan-TPP-pCpG-si1sh1 decreased cALT1 and cALT2 expression to 53 % and 72 %, 
respectively, of the values observed in S. aurata fed diet P60, and to 55 % and 57 %, 
respectively, of the mRNA levels in those fed diet P45. Knockdown of cALT expression 
caused a concomitant decrease in ALT activity to 59 % and 74 % of the values determined in 
control animals fed diets P60 and P45, respectively. cALT silencing mediated by chitosan-
TPP-pCpG-si1sh1 did not affect mALT expression levels irrespective of the diet supplied.  
 In order to unravel functional genomic effects associated with silencing of cALT 
expression, the activity of key enzymes in carbohydrate and protein metabolism were also 
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determined in the liver of fish fed either diet P60 or P45 and administered with chitosan-TPP, 
chitosan-TPP-pCpG-siRNA-Scramble or chitosan-TPP-pCpG-si1sh1. In agreement with 
previous results, the hepatic activity of glycolytic enzymes PFK-1 and PK and key enzymes 
of the pentose phosphate pathway (G6P-DH and 6PG-DH) was higher in the liver of S. 
aurata fed the low protein/high carbohydrate diet (P45) (Metón et al. 1999; Fernández et al. 
2007). Knockdown of cALT expression mediated by administration of chitosan-TPP-pCpG-
si1sh1, significantly increased PFK-1 (1.4- and 1.9-fold increase compared to controls 
injected with chitosan-TPP and fed diets P60 and P45, respectively) and PK activity (2.7- and 
3.2-fold increase compared to fish injected with chitosan-TPP and fed diets P60 and P45, 
respectively) (Figs. 6a and 6b). For both enzymes, cALT silencing caused a higher effect on 
S. aurata fed diet P45. However, no significant changes were detected in the gluconeogenic 
FBPase-1 activity in the liver of animals fed either diet P60 or P45 and treated with chitosan-
TPP, chitosan-TPP-pCpG-siRNA-Scramble or chitosan-TPP-pCpG-si1sh1 (Fig. 6c). 
 A tendency to present increased activity values (about 1.2-fold) was also found for 
key enzymes of pentose phosphate pathway (G6P-DH and 6PG-DH) in the liver of S. aurata 
administered with chitosan-TPP-pCpG-si1sh1 and fed diet P60 or P45 (Figs. 7a and 7b). 
Concerning GDH, an enzyme with a major role in nitrogen balance, the highest hepatic 
activity values were observed when feeding the high protein/low carbohydrate diet (P60). 
Treatment with chitosan-TPP-pCpG-si1sh1 significantly increased GDH activity (1.7- and 







In previous studies we reported that ALT activity levels in S. aurata liver depends on the 
nutritional composition of the diet (Metón et al. 1999; Fernández et al. 2007; Anemaet et al. 
2008). Moreover, we found that the AOA-dependent inhibition of cytosolic ALT activity 
may improve the use of dietary carbohydrates in S. aurata through a mechanism involving 
increased PK activity in liver (González et al. 2012). The aim of the present study was to 
analyse functional genomic effects associated with gene knockdown of S. aurata cALT 
isoforms in liver. To this end, S. aurata fingerlings were intraperitoneally administered with 
chitosan-TPP complexed with a plasmid expressing shRNAs that encoded siRNA for 
targeting cALT isoforms. In addition to study the effect of cALT knockdown on ALT 
expression, the activity of key enzymes involved in metabolic pathways related to 
carbohydrate and protein metabolism was also determined in the liver of fish subjected to 
cALT silencing.  
In order to down-regulate the expression of cALT isoforms, we firstly validated in 
vitro different specifically designed siRNAs. At present there is no availability of a stable 
hepatic cell line derived from S. aurata that is easily transfectable, and therefore selected 
siRNAs were validated in HEK-293 cells co-transfected with constructs expressing S. aurata 
ALT isoforms. This allowed us to choose siRNA1 to perform further experiments, as it 
produced the more pronounced knockdown effect on cALT expression and did not affect 
mALT mRNA levels. siRNA1 can interact with positions 519-537 and 604-622 of cALT1 
and cALT2 mRNA sequences (GenBank no. AY206502 and DQ334748), respectively, and 
down-regulate both cALT1 and cALT2 expression. In fact, siRNA1 targets both isoforms, 
which are produced by alternative splicing of cALT gene (Anemaet et al. 2008). However, in 
vitro and in vivo data indicate that siRNA1 appeared to silence cALT1 expression somewhat 
more efficiently than cALT2, possibly as a result of secondary structure differences between 
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cALT1 and cALT2 messengers. Indeed, cALT1 lacks an extra 85 bp-exon present in cALT2 
(Anemaet et al. 2008). 
Based on in vitro results with siRNA1, and with the intention of extending siRNA1 
half-life inside the cells, a siRNA1-based shRNA was designed and cloned into pCpG-siRNA 
to obtain pCpG-si1sh1. In fish species other than zebrafish, siRNAs for gene silencing was 
firstly used in rainbow trout embryos. The authors showed the ability of specific siRNAs to 
target foreign and endogenous cell gene expression (Boonanuntanasarn et al. 2003). Since 
then, a few studies have reported the use of shRNAs to produce siRNAs and knockdown the 
expression of specific genes in fish-derived cell lines and fish species (Su et al. 2008; Zenke 
and Kim 2008; Terova et al. 2013). Our in vitro results indicate that administration of a 
shRNA-based vector (pCpG-si1sh1) can be efficiently used to knockdown cALT mRNA 
levels, and thus reduce the economic cost of using synthesised siRNAs. 
Based on its beneficial properties compared to viral vectors, chitosan-DNA complexes 
have increased their use as carrier systems for nucleic acids delivery into cells in culture or 
animal tissues (Kiang et al. 2004; Huang et al. 2005; Lavertu et al. 2006; Howard et al. 2006; 
Katas and Alpar 2006; Wang et al. 2009; Mao et al. 2010; Techaarpornkul et al. 2010; 
Ballarín-González et al. 2013). The low toxicity and the capacity of chitosan to form 
nanoparticles with nucleic acids represent good characteristics to explore the potential of 
chitosan-DNA particles for hepatic ALT expression silencing and its downstream metabolic 
effects. In this regard, it was reported that chitosan nanoparticles complexed with DNA 
located mainly in liver and kidney following intravenous injection in mice, causing minimal 
toxicity effects (Mao et al. 2001). In the present study, intraperitoneal administration of 
chitosan-TPP complexed with the empty vector pCpG-siRNA allowed us to detect expression 
of bacterial b-galactosidase alpha peptide in the S. aurata liver, which suggests that the use of 
chitosan-TPP complexed with plasmid DNA could be a good strategy to analyse functional 
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genomic effects caused after silencing cALT expression in the liver. Furthermore, no damage 
or death of animals was found after treatment with chitosan-TPP-DNA particles. Therefore, 
we have used chitosan-TPP-pCpG-si1sh1 nanoparticles in order to express a specific shRNA 
with the aim to induce a siRNA-mediated knockdown of cALT expression in the S. aurata 
liver and to study functional genomic effects derived from cALT silencing in vivo.  
Our findings indicate that intraperitoneal delivery of chitosan-TPP-pCpG-si1sh1 
nanoparticles to S. aurata down-regulated hepatic mRNA levels of both cALT1 and cALT2 
and caused a concomitant decrease in ALT activity irrespective of the diet supplied. 
Consistent with previous observations, the highest cALT1 and cALT2 expression and ALT 
activity values were found in the group of animals fed the high protein/low carbohydrate diet 
(P60). This results confirm that the expression of cALT isoforms represents a biomarker that 
is sensitive to fish nutritional status and changes in the nutrient composition of the diet 
(Metón et al. 1999; Fernández et al. 2007). 
To analyse the effect of cALT knockdown on the S. aurata intermediary metabolism, 
activity of key enzymes in glycolysis, gluconeogenesis, pentose phosphate pathway and 
protein metabolism was determined in the liver of S. aurata treated with chitosan-TPP-pCpG-
si1sh1. Silencing of cALT isoforms led to increased activity of glycolytic enzymes (PFK-1 
and PK), whereas did not affect the gluconeogenic FBPase-1. Concerning the glycolytic 
enzymes, the effect of cALT down-regulation was significantly more pronounced when 
feeding the low protein/high carbohydrate diet (P45). In this regard, the hepatic activity of 
PFK-1 and PK were previously found to correlate positively with the carbohydrate content of 
the diet and negatively with dietary protein in S. aurata (Metón et al. 1999; Fernández et al. 
2007). Taken together, our findings suggest that cALT knockdown stimulates the glycolytic 
flux in the S. aurata liver. In a previous study where cytosolic ALT activity was inhibited by 
addition of AOA, we also reported increased PK activity in this species (González et al. 
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2012). Interestingly, a tendency to increase activity of key enzymes in the oxidative phase of 
the pentose phosphate pathway (G6P-DH and 6PG-DH) was also observed in the liver of S. 
aurata treated with chitosan-TPP-pCpG-si1sh1 nanoparticles, supporting that carbohydrate 
mobilisation occurs in the liver as a result of decreased cALT expression. 
Moreover, silencing of cALT expression increased hepatic GDH activity. S. aurata 
fed the high protein/low carbohydrate diet (P60) exhibited the highest GDH activity levels as 
a result of cALT down-regulation. GDH links amino acids, carbohydrate metabolism and 
cellular bioenergetic processes by producing a-ketoglutarate, which can replenish 
tricarboxylic acid cycle intermediates or generate glutamate for metabolic purposes. 
Contradictory results have been reported regarding the effect of dietary nutrients on GDH 
activity (Cowey and Walton 1989; Gómez-Requeni et al. 2003; Figueiredo-Silva et al. 2010; 
Liu et al. 2012). This may be explained by the fact that GDH undergoes a complex allosteric 
regulation by amino acids and metabolites, such as activation by ADP and leucine, and 
inhibition by GTP, ATP and palmitoyl-CoA (Stanley 2009). The rationale behind increased 
GDH activity resulting from silenced cALT expression in the S. aurata liver remains unclear. 
In conclusion, our results demonstrate for the first time that chitosan-TPP particles 
complexed with a shRNA expression vector, can efficiently knockdown mRNA levels of 
cALT isoforms in vivo. Indeed, down-regulation of ALT expression in liver of S. aurata 
might be a good strategy to improve the use of dietary carbohydrates as metabolic fuel, via 
glucose oxidation through glycolysis or the pentose phosphate pathway, and thus promote the 
sparing of dietary protein catabolism and increase its utilisation for growth. Development of 
long-term nucleic acid delivery methods to silence gene expression in vivo will be necessary 
to further assess the effects of cALT silencing on the use of dietary carbohydrates and growth 
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Table 1. Composition of the diets supplied to S. aurata in this study. 
 P60 P45 Microbaq 
Formulation (%)    
    Mineral mixturea 0.9 0.9 1.7 
    Brown fish mealb 84.7 63.9 60.5 
    Fish oilc 5.0 8.4 13.5 
    Starchd 7.2 24.6 - 
    Wheat meal - - 11.4 
    Wheat gluten - - 8.3 
    Soluble fish extract - - 2.5 
    Yeast extract - - 1.0 
    Soy lecithin - - 1.0 
    Vitamin mixturee 0.2 0.2 0.1 
    Carrageenanf 2.0 2.0 - 
    
Chemical analysis (%)    
    Protein 60 45.3 51.0  
    Carbohydratesg 7.2 24.6 16.3  
    Fat 14.7 15.7 20.1  
    Moisture 2.3 1.7 2.1  
    Celluloses 1 1 0.5  
    Phosphate 1.3 1.3 1.2  
    Ash 14.6 11.2 10.5  
    Gross energy (kJ/g)h 21.3 21.2 23.0  
 
aMineral mixture provided (mg/Kg): CaHPO4·2H2O, 7340; MgO, 800; KCl, 750; 
FeSO4·7H2O, 60; ZnO, 30; MnO2, 15; CuSO4·5H2O, 1.7; CoCl2·6H2O, 1.5; KI, 1.5; 
Na2SeO3, 0.3. bCorpesca S.A. Super-Prime fish meal (Santiago de Chile, Chile). cCod liver oil 
from A.F.A.M.S.A. (Vigo, Spain). dPregelatinised corn starch from Brenntag Química S.A. 
(St. Andreu de la Barca, Barcelona, Spain). eVitamin mixture provided (mg/Kg): choline 
chloride, 1200; myo-inositol, 400; ascorbic acid, 200; nicotinic acid, 70; all-rac-tocopherol 
acetate, 60; calcium pantothenate, 30; riboflavin, 15; piridoxin, 10; folic acid, 10; menadione, 
10; thiamin-HCl, 8; all-trans retinol, 2; biotin, 0.7 cholecalciferol, 0.05; cyanocobalamin, 
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0.05. fIota carrageenan (Sigma-Aldrich). gCarbohydrates were calculated by difference. 
hCalculated from gross composition (protein 24 kJ/g, lipids 39 kJ/g, carbohydrates 17kJ/g). 
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Table 2. Primers used in the present study. 




























The following primers contain restriction sites indicated in bold and underlined: JDAL16, 





Fig. 1. siRNA-mediated down-regulation of S. aurata cALT isoforms in HEK-293 cells 
expressing piscine cALT1, cALT2 and mALT. a HEK-293 cells grown in 6-well plates were 
transfected with or without siRNA1 (20 nM), different amounts of an expression plasmid 
encoding S. aurata cALT1 (3 ng, 30 ng or 300 ng) and CMV-b (300 ng). Twenty-four h 
following transfection, cells were lysed and RNA isolated. b HEK-293 cells grown in 6-well 
plates were transfected with or without siRNA1 (20 nM), an expression plasmid encoding S. 
aurata cALT1 (30 ng) and CMV-b (300 ng). Cells were lysed and RNA isolated at 24 h, 48 h 
and 72 h following transfection. c HEK-293 cells grown in 6-well plates were transfected 
with or without siRNA1 (50 nM), 30 ng of expression plasmids encoding S. aurata cALT2 
and mALT and CMV-b (300 ng). Twenty-four h following transfection, cells were lysed and 
RNA isolated. mRNA levels of S. aurata ALT isoforms relative to b-galactosidase (internal 
control of transfection) and human HPRT were determined by qRT-PCR. Normalised mRNA 
levels in the cells transfected without siRNA1 were set at 1. The data represent the mean ± 
S.D. values of three independent experiments performed in duplicate. Statistical significance 
related to cells transfected without siRNA1 is indicated as follows: **P < 0.01; ***P < 
0.001.  
 
Fig. 2. shRNA-mediated down-regulation of S. aurata cALT1 expressed in HEK-293 cells. 
HEK-293 cells grown in 6-well plates were transfected with different amounts of pCpG-
si1sh1 (0, 30 ng, 300 ng or 600 ng), an expression plasmid encoding S. aurata cALT1 (30 ng) 
and CMV-b (300 ng). Forty-eight h following transfection, cells were lysed and RNA 
isolated. mRNA levels of S. aurata cALT1 relative to b-galactosidase (internal control of 
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transfection) and human HPRT were determined by qRT-PCR. Normalised mRNA levels in 
the cells transfected in the absence of pCpG-si1sh1 were set at 1. The data represent the mean 
± S.D. (n=7). Statistical significance related to cells transfected in the absence of pCpG-
si1sh1 is indicated as follows: **P < 0.01. 
 
Fig. 3. Atomic force microscopy images of chitosan-TPP-pCpG-siRNA nanoparticles and 
expression of Escherichia coli b-galactosidase alpha peptide in liver of S. aurata 
administered with chitosan-TPP-pCpG-siRNA. a Atomic force microscopy images of 
chitosan-TPP (panel a) and chitosan-TPP-pCpG-siRNA (panel b) nanoparticles. Average 
particle size for chitosan-TPP and chitosan-TPP-pCpG-siRNA were measured on three 
samples of each nanoparticle preparation. b Two groups of five fish fed 20 d at a daily ration 
of 2 % BW with Microbaq diet were intraperitoneally injected with chitosan-TPP or chitosan-
TPP-pCpG-siRNA (10 µg of plasmid per gram BW). The mRNA levels of E. coli b-
galactosidase alpha peptide were analysed by semi-quantitative RT-PCR in the S. aurata liver 
24 h following treatment. PCR products corresponding to individual samples were size-
fractionated by electrophoresis on a 1% agarose gel and visualised by ethidium bromide 
staining. 
 
Fig. 4. Effect of cALT silencing on the expression of ALT isoforms in liver of S. aurata. 
Three groups of fish fed 20 d at a daily ration of 2 % BW with Microbaq diet were 
intraperitoneally injected with chitosan-TPP (-), chitosan-TPP-pCpG-siRNA-Scramble 
(Scramble; 10 µg of plasmid per gram BW) or chitosan-TPP-pCpG-si1sh1 (si1sh1; 10 µg of 
plasmid per gram BW). a Immunodetection of ALT protein in liver crude extracts, and 
analysis of hepatic cALT1 and cALT2 mRNA levels relative to S. aurata b-actin by qRT-
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PCR were performed 72 h following treatment. Normalised mRNA levels in the fish 
administered with chitosan-TPP were set at 1. Expression data represent the mean ± S.D. 
values (n=6). b ALT and AST specific activity values were determined in the fish liver 72 h 
following treatment. The data represent the mean ± S.D. values (n=4). Statistical significance 
related to the fish administered with chitosan-TPP is indicated as follows: *P < 0.05, **P < 
0.01. 
 
Fig. 5. Effect of cALT silencing on the expression of ALT isoforms in liver of S. aurata fed 
diets differing in nutrient composition. Three groups of fish fed 25 d at a daily ration of 2 % 
BW with either diet P60 or diet P45 were intraperitoneally injected with chitosan-TPP (-), 
chitosan-TPP-pCpG-siRNA-Scramble (Scramble; 10 µg of plasmid per gram of BW) or 
chitosan-TPP-pCpG-si1sh1 (si1sh1; 10 µg of plasmid per gram of BW). (Analyses were 
performed on liver samples obtained 72 h following treatment. a The mRNA levels of cALT1 
relative to S. aurata b-actin were determined by qRT-PCR. b The mRNA levels of cALT2 
relative to S. aurata b-actin were determined by qRT-PCR. c The mRNA levels of mALT 
relative to S. aurata b-actin were determined by qRT-PCR. d ALT activity was assayed in 
liver extracts. The data represent the mean ± S.D. values (n=7-11). Statistical significance for 
independent variables (Diet and Treatment) and the interaction between independent 
variables are indicated as follows: **P < 0.01; ***P < 0.001; NS, not significant. 
Homogeneous subsets for the independent variable involving three groups or more 
(Treatment) is indicated with different letters (P < 0.05). 
 
Fig. 6. Effect of cALT silencing on the activity of key enzymes in glycolysis-
gluconeogenesis in liver of S. aurata. Three groups of fish fed 25 d at a daily ration of 2 % 
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BW with either diet P60 or diet P45 were intraperitoneally injected with chitosan-TPP (-), 
chitosan-TPP-pCpG-siRNA-Scramble (Scramble; 10 µg of plasmid per gram BW) or 
chitosan-TPP-pCpG-si1sh1 (si1sh1; 10 µg of plasmid per gram BW). Enzyme activities were 
assayed on liver extracts from tissue samples obtained 72 h following treatment. a PFK-1 
activity. b PK activity. c FBPase-1 activity. The data represent the mean ± S.D. values (n=7-
13). Statistical significance for independent variables (Diet and Treatment) and the 
interaction between independent variables are indicated as follows: **P < 0.01; ***P < 
0.001; NS, not significant. Homogeneous subsets for the independent variable involving three 
groups or more (Treatment) are indicated with different letters (P < 0.05). 
 
 
Fig. 7. Effect of cALT silencing on the activity of key enzymes in pentose phosphate 
pathway and GDH in liver of S. aurata. Three groups of fish fed 25 d at a daily ration of 2 % 
BW with either diet P60 or diet P45 were intraperitoneally injected with chitosan-TPP (-), 
chitosan-TPP-pCpG-siRNA-Scramble (Scramble; 10 µg of plasmid per gram BW) or 
chitosan-TPP-pCpG-si1sh1 (si1sh1; 10 µg of plasmid per gram BW). Enzyme activities were 
assayed on liver extracts from tissue samples obtained 72 h following treatment. a G6P-DH 
activity. b 6PG-DH activity. c GDH activity. The data represent the mean ± S.D. values (n=7-
13). Statistical significance for independent variables (Diet and Treatment) and the 
interaction between independent variables are indicated as follows: **P < 0.01; ***P < 
0.001; NS, not significant. Homogeneous subsets for the independent variable involving three 
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                 Treatment 
Interaction Diet Treatment − Scramble si1sh1 
cALT1 mRNA NS NS *** b b a 
cALT2 mRNA NS *** ** b b a 
mALT mRNA NS NS NS - - - 
ALT activity NS *** ** b b a 
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   Treatment 
Interaction Diet Treatment − Scramble si1sh1 
PFK-1 activity ** *** *** a a b 
PK activity *** *** *** a a b 
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   Treatment 
Interaction Diet Treatment − Scramble si1sh1 
G6P-DH activ. NS * NS - - - 
6PG-DH activ. NS *** NS - - - 
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